Quoin Pharmaceuticals Stock
Quoin Pharmaceuticals, Ltd.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael Myers
- Employees
- 4
- Market cap
- $8 M
- IPO
- 01/08/2016
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing…
Quoin Pharmaceuticals stock: price history
1D
-3.2%
1W
-13.3%
1M
-43.5%
6M
-39.6%
YTD
-73.0%
1Y
-71.2%
2Y
-85.9%
5Y
-100.0%
10Y
-100.0%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~4% weaker price swings than usual
Ask the agents about Quoin Pharmaceuticals
Analyst assessment of Quoin Pharmaceuticals
PRICE TARGET LOW
US$14.00
CONSENSUS
US$17.00
MEDIAN
US$17.00
PRICE TARGET HIGH
US$20.00
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 15/03/2024
Quoin Pharmaceuticals stock metrics
P/E
-0.26
P/B
1.99
EV/EBITDA
-0.21
RETURN ON EQUITY
-138.9%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
71.8%
FLOAT SHARES
1,441,405
AVG. DAILY VOLUME (30D)
53,422
Insider transactions (SEC)
Culverwell Anthony James
Lawlor Sally Bridget
Myers Michael
Carter Denise P.
Culverwell Anthony James
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Quoin Pharmaceuticals stock
What does Quoin Pharmaceuticals do?
Quoin Pharmaceuticals, Ltd. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael Myers, the company employs around 4 people.
The IPO was on 01/08/2016; the stock trades on NASDAQ under the ticker QNRX.
What do analysts say about Quoin Pharmaceuticals stock?
4 analysts rate the stock, the consensus is Buy (as of 15/03/2024).
The average price target is US$17.00, ranging from US$14.00 to US$20.00, with a median of US$17.00.
This is an external assessment, not a statement by Market Jury.
When does Quoin Pharmaceuticals report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -4% stronger than usual.
Does Quoin Pharmaceuticals pay a dividend?
No, Quoin Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Quoin Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Quoin Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Quoin Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.